Essentials Diabأ¨te: Faits saillants du 71e sessions ...img. Essentials Diabأ¨te: Faits saillants du

  • View
    0

  • Download
    0

Embed Size (px)

Text of Essentials Diabأ¨te: Faits saillants du 71e sessions ...img. Essentials Diabأ¨te: Faits...

  • Essentials Diabète: Faits saillants du 71e sessions scientifiques CME Supported by an independent educational grant from

    View this activity online at:

    medscape.org/lecture/diabetes-fr

    and

  • Pg.2

    Diabetes Essentials: Höhepunkte aus der 71. Scientific Sessions CME

    This article is a CME/CE certified activity. To earn credit for this activity visit:

    medscape.org/lecture/diabetes-fr

    CME/CE Released: 07/13/2011; Valid for credit through 07/13/2012

    Target Audience This activity is intended for endocrinologists, diabetologists, family medicine and internal medicine physicians, and allied healthcare professionals (nurse practitioners, physician assistants, and diabetes educators) who treat patients with type 2 diabetes

    Goal The goal of this activity is to provide healthcare providers with expert perspectives and education on new data released at the ADA Scientific Sessions on emerging therapies in type 2 diabetes and their clinical application to improve the management of patients with diabetes.

    Learning Objectives Upon completion of this activity, participants will be able to:

    1. Interpret new clinical trial data on emerging antidiabetic agents and novel therapeutic approaches to comprehensive diabetes management

    Credits Available Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Accreditation Statements This education initiative is in collaboration with the American Diabetes Association’s: 71st Scientific Sessions, June 24 – 28 – 2011– San Diego, CA

    For Physicians Medscape, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Instructions for Participation and Credit There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

    This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during

  • medscape.org/lecture/diabetes-fr

    Pg.3

    the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

    Follow these steps to earn CME/CE credit*:

    1. Read the target audience, learning objectives, and author disclosures.

    2. Study the educational content online or printed out.

    3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for future programming.

    You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing “Edit Your Profile” at the top of your Medscape homepage.

    *The credit that you receive is based on your user profile.

    Hardware/Software Requirements To access Medscape Education users will need • A computer with an Internet connection. • Internet Explorer 6.x or higher, Firefox 2.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser. • Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback. • Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader.

    Authors and Disclosures As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

    Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

    Author Mark E. Molitch, MD Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Disclosure: Mark E. Molitch, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: sanofi-aventis; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Corcept Therapeutics Inc. Received grants for clinical research from: sanofi-aventis; Novartis Pharmaceuticals Corporation; Corcept Therapeutics Inc.; Ipsen; Reata Pharmaceuticals, Inc.

    Dr. Molitch does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the US Food and Drug Administration (FDA) for use in the United States.

    Dr. Molitch does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

    Editor Anne G. Le, PharmD, RPh Scientific Director, Medscape, LLC Disclosure: Anne G. Le, PharmD, RPh, has disclosed no relevant financial relationships.

    CME Reviewer Nafeez Zawahir, MD CME Clinical Director, Medscape, LLC Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

  • Pg.4

    Diabetes Essentials: Höhepunkte aus der 71. Scientific Sessions CME

    Note du rédacteur: Ce programme comprend des discussions sur les agents d’investigation n’est pas approuvé par la Food and Drug Administration américaine (FDA) pour une utilisation aux États-Unis et off-label utilisations de médicaments approuvés par la FDA pour une utilisation aux États-Unis.

    Einführung

    Dr Mark E. Molitch: Bonjour, Je suis le Dr Mark Molitch. Je suis professeur de médecine à l’école de médecine Feinberg de l’université du Nord-Ouest à Chicago, dans l’Illinois. Je suis ravi de vous accueillir à ce programme intitulé “Le diabète au quotidien : points principaux essentiels de l’ADA (Association Américaine contre le Diabète).

    La discussion d’aujourd’hui a pour objet principal de fournir un contexte clinique aux données présentées récemment lors des 71e Sessions scientifiques de l’ADA sur les traitements émergents du diabète de type 2 en prêtant plus particulièrement attention aux traitements à base d’incrétine et aux inhibiteurs du SGLT-2 (transporteur sodium/glucose de type 2) encore à l’étude.

  • medscape.org/lecture/diabetes-fr

    Pg.5

    Nous nous servirons également de mini sondages interactifs afin de mieux comprendre votre pratique clinique et votre niveau de compréhension des traitements plus récents du diabète de type 2.

    Avant de commencer, j’aimerais vous faire remarquer que cette activité comprendra une discussion sur les médicaments à l’étude qui n’ont pas encore été approuvés par la FDA. Nous allons discuter d’études publiées sous forme d’abrégés et présentées lors des Sessions scientifiques de l’ADA de 2011. Ces études et les données qui leur correspondent doivent par conséquent être considérées comme préliminaires jusqu’à ce qu’elles fassent l’objet d’une publication dans une revue spécialisée.

  • Pg.6

    Diabetes Essentials: Höhepunkte aus der 71. Scientific Sessions CME

    Mini sondage 1

    Passons au premier mini sondage.

    Question: Quelle proportion de vos patients atteints de diabète de type 2 atteint un taux d’hémoglobine glycosylée (A1c) < 7.0% avec son traitement actuel ?

    Answer Choices

    l Moins de 25%

    l Entre 25 et 50%

    l Entre 50 et 75%

    l Plus de 75%

    Avancées dans le domaine du traitement du diabète de type 2

  • medscape.org/lecture/diabetes-fr

    Pg.7

    Au cours de ces 10-15 dernières années, nous avons certainement assisté à des avancées et à des progrès formidables en matière de traitement du diabète de type 1. L’étude EDIC (Epidemiology of Diabetes Intervention and Complications), qui est en fait un suivi au long terme effectué après l’étude DCCT (Diabetes Control and Complications Trial) sur le contrôle du diabète et de ses complications, a montré les avantages continus d’un contrôle glycémique strict sur les complications microvasculaires du diabète.

    Les récentes études ADVANCE [Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation], ACCORD [Action to Control Cardiovascular Risk in Diabetes], et VADT [Veterans Affairs